Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations

Serisier, D. J. and Martin, M. L. (2011) Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respiratory Medicine, 105 6: 946-949. doi:10.1016/j.rmed.2011.01.009

Author Serisier, D. J.
Martin, M. L.
Title Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations
Journal name Respiratory Medicine   Check publisher's open access policy
ISSN 0954-6111
Publication date 2011-06-01
Sub-type Article (original research)
DOI 10.1016/j.rmed.2011.01.009
Open Access Status Not Open Access
Volume 105
Issue 6
Start page 946
End page 949
Total pages 4
Place of publication Oxford, United Kingdom
Publisher Elsevier
Language eng
Formatted abstract
Background: Macrolide antibiotics are increasingly prescribed for subjects with non-cystic fibrosis (CF) bronchiectasis, an empiric extension of their proven efficacy in CF. Widespread, injudicious use of long-acting macrolides, particularly azithromycin, risks significantly increasing population antimicrobial resistance.
Methods: In an attempt to power a definitive randomised-controlled trial (RCT), an uncontrolled evaluation of the impact of long-term, low-dose oral erythromycin therapy upon pulmonary exacerbation frequency in non-CF bronchiectasis subjects was performed. Adult bronchiectasis subjects with at least 2 infective exacerbations in the preceding 12 months were followed for 12 months following commencement of prophylactic oral erythromycin 250 mgs daily. The co-primary outcome measures, comparing the 12 month erythromycin and pre-erythomycin periods, were numbers of infective exacerbations and days of antibiotic therapy for infective exacerbations.
Results: In the 24 evaluable subjects completing a minimum of 12 months of therapy, erythromycin was associated with halving of both the median (range) annual number of infective exacerbations (2 (0—8) vs 4 (2—11), 95% CI 1.5 to 3.5, p < 0.0001) and annual days of antibiotic use (21 (0—78) vs 44 (15—138), 95% CI 18 to 40, p< 0.0001) compared with the preceding 12 month period.
Conclusions: Low-dose erythromycin may have a robust effect upon exacerbation frequency in non-CF bronchiectasis subjects with frequent exacerbations and this warrants proceeding to a definitive intervention study. These data have enabled powering of an RCT of long-term, lowdose erythromycin, which is now underway and also incorporates bronchoscopic evaluation for pathophysiologic data.
Keyword Bronchiectasis
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2012 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 38 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 46 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 13 Apr 2012, 21:45:37 EST by System User on behalf of Medicine - Mater Hospital